Nivéstor

stocks · Monday, June 15, 2026 · 4 min

Buy Summit at $14.40 after the founder bet $100 million of his own money on the panic low

Summit Therapeutics' executive chairman Robert Duggan bought 7.67 million shares for about $100.7 million on June 4 at $13.13, right as the stock cratered to a 52-week low and the market sentiment gauge hit 13 out of 100. Buy SMMT at $14.40 and sell if it closes under $12.40.

$SMMT$MRK
Your guide

Your guide reads 50+ feeds so you do not have to. Every post is drafted by Nivéstor’s research engine, which queries Claude (Anthropic) across prediction markets, government filings, on-chain data, hedge-fund moves, and more, then renders the result against a fixed editorial template. No human edits the draft before publication. Methodology · Track record.

BUY
$SMMT
Pay around $14.40
Don't pay more than $14.62
Get out at $12.40
Use 5% of your money
Watch out for next lung-cancer Phase 3

Aim for $18.40: the 50-day moving average and the late-May consolidation top at $18.66, where the prior sell-off began

Aim for $22.00: the April 24 to 29 consolidation top before the May 1 crash, also near the 200-day moving average at $18.11 plus a typical biotech recovery extension

Why this size: Risk 1% of the account at the sell-if-it-drops level. Distance from $14.40 to $12.40 is 13.9% of entry, so size = 1% / 13.9% = 7.2% of account. Cut to 5% because single-name biotech with a binary trial readout can gap 30% to 50% past the sell level overnight.

When you'd hold this: 2 to 6 months, around next lung-cancer Phase 3 trial readout (HARMONi-3) expected in the second half of 2026; no exact date filed

On June 4, while Summit Therapeutics' stock was bottoming out near $13, the company's executive chairman Robert Duggan bought 7,670,000 shares for about $100.7 million of his own money. The filing hit the public record on June 121. Today the stock is at $14.40, up roughly 10% from his average buy price, while the wider market's fear gauge is still pinned in extreme fear at 20 out of 100. That kind of personal bet at a panic low is the cleanest signal an outside investor can ride.

What just happened

Summit Therapeutics is a small drug company whose only meaningful product is a lung-cancer treatment called ivonescimab, which it licensed from a Chinese partner. The stock peaked near $29 in late April after good trial news, then collapsed to a low of $12.55 on June 10. Cause of the drop: a mix of disappointing follow-on trial updates, broad biotech selling, and worry that anything tied to a Chinese drug partner could face political friction.

On June 4, with the share price right at the bottom, Robert Duggan (the company's executive chairman, biggest shareholder, and the guy who built and sold the cancer-drug company Pharmacyclics to AbbVie for $21 billion in 2015) bought another 7.67 million shares for cash1. That is not a $1,000 board-meeting purchase to look loyal. That is $100 million from one person, filed publicly, at the panic low.

The market sentiment gauge from CNN read 13 on June 13, the day after the filing was published, and 20 today. Anything under 25 historically marks the kind of fear level where contrarian buyers get rewarded over a few months.

So what

Follow the chain. Duggan already owns more than a billion shares of Summit, so he does not need more for control. He bought because he believes today's price is materially below what the drug will be worth once the next big trial readout lands. Which means he expects the readout to be good, and he expects it within a horizon worth paying $100 million to get in front of. Which means the company's silence about an exact date is not bad news, it is just timing. Which is why a buyer at $14.40 today is, in effect, getting the same trade as the guy with the most insider knowledge possible, at a 10% premium to his fill, with a clean sell level at the panic low he already defended.

A second thread runs alongside. The wider market is in extreme fear today, the same regime that produced the lows in October 2022 and March 2020. When fear is this deep, small biotechs with binary catalysts get sold indiscriminately, not for company-specific reasons. The founder is buying that mispricing, not just his own drug.

What to do about it

Buy SMMT around $14.40 and do not pay more than $15.50. Sell if it closes under $12.40, which is below the June 10 panic low; if that level breaks, the panic was not the bottom. First place to take some profit is around $18.40, near the May consolidation top and the 50-day average. Second target is around $22, near where the April sell-off began. Keep the position to roughly 5% of the account because a small biotech with a single drug and a future trial readout can gap 30% or more past your sell-if-it-drops level in one morning if the data is bad.

Main risk: the next trial readout disappoints, or the U.S. government acts against drugs licensed from Chinese partners, in which case all bets are off.

What we got right (and wrong) before

Last week we said buy MasterBrand at $8.80 after a director bought $650,000, on the same template: panic low plus a real insider check signed. That post is still open and the stock is hovering near the buy level. The pattern works best when the dollar amount of the buy is large relative to the executive's net worth, which is why a $100 million buy from one person here is in a different class from any insider trade we've flagged this quarter.

For the nerds

SMMT spot $14.40, RSI 14 at 31.89 (weakening, approaching oversold), MACD -1.24 with signal -1.16 and histogram -0.09 (bearish but flattening), price $14.40 vs SMA-50 $18.40 vs SMA-200 $18.11, 52-week range $12.55 to $30.98. Short volume ratio on FINRA consolidated tape 41.5% (June 12), not crowded. Form 4 filing1 shows Robert L. Duggan as a 10% owner, executive chairman, and CEO, 7,670,000 shares purchased at $13.13 on 2026-06-04 for $100,696,650, post-trade stake 1,223,155,221 shares. CNN Fear & Greed2 readings 13 / 18 / 20 over June 13 to 15. Berkshire 13F3 shows the most-watched value fund cut Chevron 35.17% and trimmed Bank of America 0.71%, consistent with extreme-fear positioning.

Not financial advice. Do your own research.

What we passed on

  • $AMDPENDING-0.4% since pass

    Already up 8.5% today and over 350% off the 52-week low, with a tier-2 sell-side note out at $450; do not chase a stock printing new highs on a green candle.

  • $IBPPENDING-1.4% since pass

    Director bought $1 million at $207, but the stock is also near 52-week highs; the buy is normal-course, not a panic-low signal.

  • $EVTCPENDING-3.4% since pass

    Insider bought 23% more of his stake at $23.90, but the buy was filed June 12 for an April 8 trade; signal is too stale for an opening-session post.